Next-Generation Broad-Spectrum β-lactams
In the hospital setting, therapy for serious bacterial infections, including complicated skin and soft tissue infections, complicated intra-abdominal infections, complicated urinary tract infections, bacteremia, and pneumonia frequently must be initiated prior to knowing the identity of the pathogen. This practice is called empiric therapy. During empiric therapy it is critical that the treatment covers the appropriate bacteria. A delay in initiating the appropriate treatment has been proven to dramatically impact survival, morbidity and hospital associated costs.1 Since the bacteria is unknown, the broadest spectrum of activity possible, including multi-drug resistance gram-positive, gram-negative, and anaerobes, is desirable. Unfortunately, no single antibiotic currently approved adequately covers the range of potential bacteria.
A safe, reliable, broad-spectrum monotherapy with activity expanded to include problematic multi-drug resistant gram-positive and gram-negative pathogens would offer significant advantages to the current empiric treatment options.
VenatoRx is investigating new generation β-lactams with an extended spectrum of antibacterial activity. If successful, the resulting product would provide a valuable tool for fighting resistant bacteria.
1. Kollef, MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. 2008. Clin. Infect. Diseases 47:s3-13